Total neoadjuvant treatment (TNT) may provide a promising organ-preserving alternative to surgery for patients with stage I rectal cancer, according to a recent retrospective study. The research found that TNT achieved a 93.7% complete clinical response rate and preserved organs in 87.5% of patients, with no local recurrences observed over a median follow-up period of 20 months.
Study Findings
The study analyzed data from 16 patients with stage I rectal cancer who opted for TNT instead of the standard total mesorectal excision (TME) surgery between 2015 and 2023. Patients were divided into two groups: one group showed a partial response after initial chemoradiation and continued with consolidation chemotherapy; the other group underwent transanal full-thickness local excision but declined further surgery. Overall, 15 of the 16 patients achieved complete clinical response, and organ function was preserved in most cases. No local recurrence or distant metastases were detected during the follow-up period.
These findings suggest that TNT could allow select patients, especially those with low-lying tumors where surgery often leads to permanent stoma formation, to avoid invasive surgery while maintaining oncological safety. However, this study was limited by its small sample size, short follow-up, and single-center design, requiring cautious interpretation of the results.
Context of Neoadjuvant Therapy in Colorectal Cancer
Neoadjuvant therapy, which includes chemotherapy and radiation before surgery, has become an increasingly important strategy in managing early-stage colorectal cancers. Traditional approaches such as short-course radiotherapy or long-course chemoradiotherapy mainly reduce local tumor burden but have had limited effects on preventing systemic relapse. TNT, which integrates systemic chemotherapy prior to surgery, aims to enhance the local tumor response and decrease the risk of distant metastases. Emerging evidence supports its use in locally advanced colon and rectal cancers to improve outcomes.
The selective use of TNT may represent an evolution in the treatment paradigm by maximizing tumor control and minimizing the morbidity associated with surgery, especially for patients wishing to preserve rectal function and avoid permanent colostomy.
Limitations and Need for Further Research
The authors acknowledge that the study’s retrospective nature, small cohort, and heterogeneous treatment sequencing limit the generalizability of the findings. The absence of a control group undergoing traditional surgery complicates definitive comparisons. Despite these limitations, the results provide valuable preliminary data supporting the potential role of TNT as an effective, less invasive alternative in early-stage rectal cancer.
Larger prospective clinical trials with extended follow-up are urgently needed to confirm the safety and efficacy of TNT, determine optimal treatment protocols, and identify patient subgroups most likely to benefit from this approach.
Why This Matters
Rectal cancer treatment that preserves organs without compromising cure rates would represent a significant advance for patients, reducing surgical complications and improving quality of life. As TNT strategies develop, they may shift practice towards personalized, less invasive treatments. For the medical community and public health, optimizing neoadjuvant approaches aligns with goals to improve cancer outcomes and enhance survivorship through treatments tailored to individual tumor biology and patient preferences.
For more comprehensive insights on cancer treatment advances, see resources from the World Health Organization and reliable oncology journals.
References
Erozkan K, Erkaya M, Miller JA, et al. Is there a role for total neoadjuvant treatment in early-stage rectal cancer? Langenbecks Arch Surg. 2025;411(1):11. doi: 10.1007/s00423-025-03895-2
Smith HG, Nilsson PJ, Shogan BD, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8(3):zrae038. doi:10.1093/bjsopen/zrae038
Read more on Globally Pulse Health.
